Assessing genetic diversity of wheat genotypes from different origins by SNP markers

Genetic diversity was investigated in a set of eleven hexaploid wheat genotypes originated from CIMMYT, Turkey in comparison with some modern European mostly originated from KWS wheat breeding program using 24 wheat SNP markers. The lowest and highest genetic dissimilarities were observed between genotypes Opus and LDO 330/06, KWS Salix and LDO 330/06, respectively. Based on cluster analysis, 38 wheat genotypes were grouped in two main clusters. Although the grouping pattern is very origin heterogeneous in each group, the grouping pattern of some genotypes appeared to be associated, to some extent. Principal coordinate analysis (PCoA) was used as an alternative way of visualizing the genotypic data. The first, second and third principal components explained 17.79%, 14.39% and 12.24% of the variation, respectively. This study can also be an indicator for breeders to evolve genotypes with diverse genetic background to achieve sustainability in wheat production, to get favorable heterotic combinations in a wheat improvement program

The influence of Fusarium infection on wheat (Triticum aestivum L.) proteins distribution and baking quality

Under artificial Fusarium infection the total glutenin content determined by chromatographic (RP-HPLC) method was significantly reduced in comparison to gliadins which were increased. Among protein types, α-GLI and HMW-GS were the highest affected. Artificial Fusarium infection significantly increased GLI/GLU ratio when compared with the natural infected samples. Artificial Fusarium infection dramatically decreased the dough mixing tolerance and had a considerable negative effect on dough energy, maximum resistance, and resistance/extensibility ratio. Disturbed GLI/GLU ratio and an increased amount of mycotoxin DON under artificial Fusarium infection showed a strong negative impact on affected functional properties of dough and bread. Total and γ-GLI as well as GLI/GLU ratio were significantly positively affected by mycotoxin DON in contrast to total GLU, HMW-GS and LMW-GS which were negatively affected. Results indicated that the stability of baking quality parameters of cultivars more tolerance to the Fusarium infection can be well define by lower accumulation of mycotoxin DON

The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge

Breast cancer is an increasing global health, gender, socioeconomic, and equity challenge. In 2020, 2·3 million women were diagnosed with breast cancer and there were 685 000 deaths worldwide.1 Not only is breast cancer the highest incident cancer globally, but it is also the most prevalent, causing more disability-adjusted life-years lost than any other malignancy. Tackling breast cancer is a formidable task for health-care systems, policy makers, and other stakeholders. The numbers of people with metastatic breast cancer who go uncounted are concerning. Cancer registries record patients initially presenting with de-novo metastatic breast cancer, but data on those who develop metastases after a diagnosis of early breast cancer are scarce. In a world focused on breast cancer cure, these uncounted people living with metastatic disease face abandonment and stigma

Trastuzumab for HER2-positive early stage breast cancer : a meta-analysis of individual patient data from 13,864 women from seven randomised trials

Background: Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxicity. We investigated the long-term benefits and risks of adjuvant trastuzumab on breast cancer recurrence and cause-specific mortality. Methods: We did a collaborative meta-analysis of individual patient data from randomised trials assessing chemotherapy plus trastuzumab versus the same chemotherapy alone. Randomised trials that enrolled women with node-negative or node-positive, operable breast cancer were included. We collected individual patient-level data on baseline characteristics, dates and sites of first distant breast cancer recurrence and any previous local recurrence or second primary cancer, and the date and underlying cause of death. Primary outcomes were breast cancer recurrence, breast cancer mortality, death without recurrence, and all-cause mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, oestrogen receptor (ER) status, and trial yielded first-event rate ratios (RRs). Findings: Seven randomised trials met the inclusion criteria, and included 13 864 patients enrolled between February, 2000, and December, 2005. Mean scheduled treatment duration was 14·4 months and median follow-up was 10·7 years (IQR 9·5 to 11·9). The risks of breast cancer recurrence (RR 0·66, 95% CI 0·62 to 0·71; p<0·0001) and death from breast cancer (0·67, 0·61 to 0·73; p<0·0001) were lower with trastuzumab plus chemotherapy than with chemotherapy alone. Absolute 10-year recurrence risk was reduced by 9·0% (95% CI 7·4 to 10·7; p<0·0001) and 10-year breast cancer mortality was reduced by 6·4% (4·9 to 7·8; p<0·0001), with a 6·5% reduction (5·0 to 8·0; p<0·0001) in all-cause mortality, and no increase in death without recurrence (0·4%, –0·3 to 1·1; p=0·35). The proportional reduction in recurrence was largest in years 0–1 after randomisation (0·53, 99% CI 0·46 to 0·61), with benefits persisting through years 2–4 (0·73, 0·62 to 0·85) and 5–9 (0·80, 0·64 to 1·01), and little follow-up beyond year 10. Proportional recurrence reductions were similar irrespective of recorded patient and tumour characteristics, including ER status. The more high risk the tumour, the larger the absolute reductions in 5-year recurrence (eg, 5·7% [95% CI 3·1 to 8·3], 6·8% [4·7 to 9·0], and 10·7% [7·7 to 13·6] in N0, N1–3, and N4+ disease). Interpretation: Adding trastuzumab to chemotherapy for early-stage, HER2-positive breast cancer reduces recurrence of, and mortality from, breast cancer by a third, with worthwhile proportional reductions irrespective of recorded patient and tumour characteristics. Funding: Cancer Research UK, UK Medical Research Council

Variability in components of fusarium head blight resistance among wheat genotypes

Fusarium head blight (FHB) is a serious threat for the quality of wheat products. In order to breed wheat lines with improved FHB resistance we investigated several FHB resistance components in Croatian and international wheat lines. We tested for Type I resistance (resistance against initial infection), Type II resistance (resistance against spreading), Type III resistance (DON resistance) and general FHB resistance. This information allows us to select proper parents used in future crosses to improve FHB resistance by combining and improving the level of individual resistance components. The genotypes Divana and SirbanProlifik showed the highest resistance levels against initial infection. The genotypes Libellula and Srpanjka had the highest resistance level against FHB spreading. The genotype Renan was the most DON resistant line